Improving the care of individuals with schizophrenia and substance use disorders: Consensus recommendations

Journal of Psychiatric Practice

Volumn 11, Issue 5, 2005, Pages 315-339

  Ziedonis, Douglas M ^a   Smelson, David ^a   Rosenthal, Richard N ^b   Batki, Steven L ^c   Green, Alan I ^d   Henry, Renata J ^e   Montoya, Ivan ^f   Parks, Joseph ^g   Weiss, Roger D ^h  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b St Luke's Roosevelt Hospital Center ^*  (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e Delaware Health and Social Services   (United States)

^f National Institute of Drug Abuse   (United States)

^g Missouri Department of Mental Health   (United States)

^h MCLEAN HOSPITAL   (United States)

Author keywords

Cognitive behavioral therapy; Comorbidity; Consensus recommendations; Dual diagnosis; Dual Recovery Therapy; Integrated treatment; Motivational enhancement therapy; Psychosocial interventions; Schizophrenia; Substance use disorders

Indexed keywords

ACAMPROSATE; AMFEBUTAMONE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BUPRENORPHINE; CHLORPROMAZINE; CLONIDINE; CLOZAPINE; DISULFIRAM; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; METHADONE; MIRTAZAPINE; NALTREXONE; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

AGRANULOCYTOSIS; ALCOHOL ABUSE; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONSENSUS DEVELOPMENT; DEPRESSION; DRUG DEPENDENCE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOTENSION; INFECTION; LIVER DISEASE; LUNG CANCER; MYOCARDITIS; NICOTINE REPLACEMENT THERAPY; PATIENT CARE; PSYCHOSOCIAL CARE; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SMOKING; SUBSTANCE ABUSE; TREATMENT PLANNING; WEIGHT GAIN;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; DIAGNOSIS, DUAL (PSYCHIATRY); DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; MENTAL HEALTH SERVICES; QUALITY OF HEALTH CARE; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 27544490742     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200509000-00005     Document Type: Review

References (126)

1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990;264:2511-8.
2. de Leon J. Smoking and vulnerability for schizophrenia. Schizophr Bull 1996;22:405-9.
3. Ziedonis DM. Integrated treatment of co-occurring mental illness and addiction: Clinical intervention, program, and system perspectives. CNS Spectrums 2004;9:892-904.
4. Substance Abuse and Mental Health Services Administration (SAMHSA). Report to Congress on the prevention and treatment of co-occurring substance abuse disorders and mental disorders. Washington, DC: 2002. Accessed April 18, 2005 at http://alt.samhsa.gov/reports/congress2002/index.html.
5. President's New Freedom Commission on Mental Health. July 22, 2003. Accessed April 26, 2005 at www.mentalhealthcommission.gov/reports/FinalReport/ downloads/FinalReport.pdf.
6. SAMHSA. Substance Abuse Treatment for Persons With Co-Occurring Disorders. Treatment Improvement Protocol (TIP) Series 42. DHHS Publication No. (SMA) 05-3922. Rockville, MD: SAMHSA; 2005. Accessed March 7, 2005. Available at www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat5.chapter.74073. Copies can also be ordered at http://store.health.org/catalog/results.aspx?h= publications&topic=103.
7. Sacks S, Sacks J, De Leon G, et al. Modified therapeutic community for mentally ill chemical "abusers": Background; influences; program descriptions; preliminary findings. Subst Use Misuse 1997;32:1217-59.
8. American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders: Alcohol, tobacco, and other drugs (in press).
9. Caton CLM, Shrout PE, Eagle PF, et al. Risk factors for homelessness among schizophrenic men: A case-control study. Am J Pub Health 1994;84:265-70.
10. Cuffel B, Shumway M, Chouljian T. A longitudinal study of substance use and community violence in schizophrenia. J Nerv Ment Disease 1994;182:704-8.
11. Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995;152:856-61.
12. Serper MR, Alpert M, Richardson NA, et al. Clinical effects of recent cocaine use on patients with acute schizophrenia. Am J Psychiatry 1995;152:1464-9.
13. Smelson DA, Davis CW, Di Pano R, et al. Executive and motor skill functioning among cocaine-dependent schizophrenics and non-drug-abusing schizophrenics. J Nerv Ment Dis 2002;190:200-2.
14. Soyka M, Albus M, Immler B, et al. Psychopathology in dual diagnosis and non-addicted schizophrenics: Are there differences? Eur Arch Psychiatry Clin Neurosci 2001;251:232-8.
15. Drake RE, Essock SM, Shaner A, et al. Implementing dual diagnosis services for clients with severe mental illness. Psychiatr Serv 2001;52:469-76.
16. Bellack AS, DiClemente CC. Treating substance abuse among patients with schizophrenia. Psychiatr Serv 1999;50:75-80.
17. Carey KB. Reliability and validity of the time-line follow-back interview among psychiatric outpatients: A preliminary report. Psychol Addict Behav 1997;11:26-33.
18. Rosenthal RN, Hellerstein DJ, Miner CR. A model of integrated services for outpatient treatment of patients with comorbid schizophrenia and addictive disorders. Am J Addict 1992;1:339-48.
19. Rosenthal RN. Mental illness/chemical addiction: A guide to emergency services assessment and treatment manual. NY State Office of Mental Health, Division of Clinical Support Systems, Albany, 1992.
20. Shaner A, Eckman T, Roberts LJ, et al. Feasibility of a skills training approach to reduce substance dependence among individuals with schizophrenia. Psychiatr Serv 2003;54:1287-9.
21. Ziedonis D, Steinberg ML, Smelson D, et al. Co-occurring addictive and psychotic disorders. In: Graham AW, Schultz TK, Mayo-Smith MF, et al., eds. Principles of addiction medicine, 3rd edition. Chevy Chase, MD: American Society of Addiction Medicine; 2003:1297-1320.
22. Ziedonis DM, Kosten TR, Glazer WM, et al. Nicotine dependence and schizophrenia. Hosp Community Psychiatry 1994;45:204-6.
23. Teitelbaum LM, Carey KB. Tips on using the Addiction Severity Index in psychiatric settings. The Behavior Therapist 1997;20:19-21.
24. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project Early Detection of Persons with Harmful Alcohol Consumption II. Addiction 1993;88:791-804.
25. Skinner HA, Sheu WJ. Reliability of alcohol use indices. The Lifetime Drinking History and the MAST. J Stud Alcohol 1982;43:1157-70.
26. Skinner HA. The Drug Abuse Screening Test. Addict Behav 1982;7:363-71.
27. Rosenberg SD, Drake RE, Wolford GL, et al. Dartmouth Assessment of Lifestyle Instrument (DALI): A substance use disorder screen for people with severe mental illness. Am J Psychiatry 1998;155:232-8.
28. Carey KB, Correia CJ. Severe mental illness and addictions: Assessment considerations. Addict Behav 1998;23:735-48.
29. Bartels SJ, Teague GB, Drake RE, et al. Substance abuse in schizophrenia: Service utilization and costs. J Nerv Ment Dis 1993;181:227-332.
30. Mueser KT, Bellack AS, Blanchard JJ. Comorbidity of schizophrenia and substance abuse: Implications for treatment. J Consult Clin Psychol 1992;60:845-56.
31. Ziedonis DM, Fisher W. Motivation-based assessment and treatment of substance abuse in patients with schizophrenia. Dir Psychiatry 1996;16:1-8.
32. Allen JP, Litten RZ. The role of laboratory tests in alcoholism treatment. J Subst Abuse Treat 2001;20:81-5.
33. Helander A. Biological markers of alcohol use and abuse in theory and practice. In: Agarwal DP, Seitz HK, eds. Alcohol in health and disease. New York: Marcel Dekker; 2001:177-205.
34. Ziedonis DM, Trudeau K. Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model. Schizophr Bull 1997;23:229-38.
35. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: Applications to addictive behaviors. Am Psychol 1992;47:1102-14.
36. Ries RK, Ellingson T. A pilot assessment at one month of 17 dual diagnosis patients. Hosp Community Psychiatry 1990;41:1230-3.
37. Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 2001;91:31-7.
38. Mukamal KJ. Alcohol consumption and abnormalities of brain structure and vasculature. Am J Geriatr Cardiol 2004;13:22-8.
39. Centers for Disease Control and Prevention. The health consequences of smoking: A report of the Surgeon General 2004. Available at http://www.cdc.gov/ tobacco/sgr/sgr_2004/
40. Dalton SO, Laursen TM, Mellemkjaer L, et al. Risk for cancer in parents of patients with schizophrenia. Am J Psychiatry 2004;161:903-8.
41. Lichtermann D, Ekelund J, Pukkala E, et al. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry 2001;58:573-8.
42. Davidson S, Judd F, Jolley D, et al. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry 2001;35:196-202.
43. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-20.
44. Dixon L, Postrado L, Delahanty J, et al. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999;187:496-502.
45. Herran A, de Santiago A, Sandoya M, et al. Determinants of smoking behaviour in outpatients with schizophrenia. Schizophr Res 2000;41:373-81.
46. McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004;65:634-51.
47. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49.
48. McCance EF, Price LH, Kosten TR, et al. Cocaethylene: Pharmacology, physiology, and behavioral effects in humans. J. Pharmacol Exp Ther 1995;274:215-23.
49. McCance-Katz EF, Kosten TR, Jatlow P. Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone: A multiple-dose study. Biol Psychiatry 1998;44:250-9.
50. Flegal KM, Cauley JA. Alcohol consumption and cardiovascular risk factors. Recent Dev Alcohol 1985;3:165-80.
51. Kuo I, Sherman SG, Thomas DL, et al. Hepatitis B virus infection and vaccination among young injection and non-injection drug users: Missed opportunities to prevent infection. Drug Alcohol Depend 2004;73:69-78.
52. Kellerman SE, Hanson DL, McNaghten AD, et al. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188:571-7.
53. Butterfield MI, Bosworth HB, Meador KG, et al. Gender differences in hepatitis C infection and risks among persons with severe mental illness. Psychiatr Serv 2003;54:848-53.
54. Stoskopf CH, Kim YK, Glover SH. Dual diagnosis: HIV and mental illness: A population-based study. Community Ment Health J 2001;37:469-79.
55. Fernandez F, Levy JK. Psychopharmacotherapy of psychiatric syndromes in asymptomatic and symptomatic HIV infection. Psychiatr Med 1991;9:377-94.
56. Batki SL. Drug abuse, psychiatric disorders, and AIDS. Dual and triple diagnosis. West J Med 1990;152:547-52.
57. Bagchi A, Sambamoorthi U, McSpiritt E, et al. Use of antipsychotic medications among HIV-infected individuals with schizophrenia. Schizophr Res 2004;71:435-44.
58. Miller WR, Rollnick S. Motivational interviewing: Preparing people to change addictive behavior. New York: Guilford; 1991.
59. Miller WR, Zweben A, DiClemente CC, et al. Motivational enhancement therapy manual. Rockville, MD: US Department of Health and Human Services, NIH Publication No. 94-3723: 1995.
60. Ziedonis DM, Stern R. Dual recovery therapy for schizophrenia and substance abuse. Psychiatr Ann 2001;31:255-64.
61. Carey KB. Substance use reduction in the context of outpatient psychiatric treatment: A collaborative, motivational, harm reduction approach. Community Ment Health J 1996;32:291-306.
62. Bartels SJ, Drake RE. A pilot study of residential treatment for dual diagnoses. J Nerv Ment Dis 1996;184:379-81.
63. Blankertz LE, Cnaan RA. Serving the dually diagnosed homeless: Program development and interventions. J Ment Health Adm 1993;20:100-12.
64. Hanson M, Kramer TH, Gross W. Outpatient treatment of adults with coexisting substance use and mental disorders. J Subst Abuse Treat 1990;7:109-16.
65. Hellerstein DJ, Rosenthal RN, Miner CR. A prospective study of integrated outpatient treatment for substance-abusing schizophrenic patients. Am J Addict 1995;4:33-42.
66. Rahav M, Rivera JJ, Nuttbrock L, et al. Characteristics and treatment of homeless, mentally ill, chemical-abusing men. J Psychoactive Drugs 1995;27:93-1.
67. Burnam MA, Morton SC, McGlynn EA, et al. An experimental evaluation of residential and nonresidential treatment for dually diagnosed homeless adults. J Addict Dis 1995;14:111-34.
68. Bennett ME, Bellack AS, Gearon JS. Treating substance abuse in schizophrenia: An initial report. J Subst Abuse Treat 2001;20:163-75.
69. Mueser KT, Bond GR, Drake RE, et al. Models of community care for severe mental illness: A review of research on case management. Schizophr Bull 1998;24:37-47.
70. Johnson B, Montgomery P. Chronic mentally ill individuals reentering the community after hospitalization. Phase II: The urban experience. J Psychiatr Ment Health Nurs 1999;6:445-51.
71. Schaedle R, McGrew JH, Bond GR, et al. A comparison of experts' perspectives on assertive community treatment and intensive case management. Psychiatr Serv 2002;53:207-10.
72. Rosenheck RA, Dennis D. Time-limited assertive community treatment for homeless persons with severe mental illness. Arch Gen Psychiatry 2001;58:1073-80.
73. Okin RL, Boccellari A, Azocar F, et al. The effects of clinical case management on hospital service use among ER frequent users. Am J Emerg Med 2000;18:603-8.
74. Witbeck G, Hornfield S, Dalack GW. Emergency room outreach to chronically addicted individuals: A pilot study. J Subst Abuse Treat 2000;9:39-43.
75. Smelson DA, Losonczy MF, Castles-Fonseca K, et al. Preliminary outcomes from a community linkage intervention for individuals with co-occurring substance abuse and serious mental illness. Journal of Dual Diagnosis 2005;1:47-59.
76. Smelson DA, Losonczy MF, Ziedonis D, et al. A brief community linkage intervention for veterans with a persistent mental illness and a co-occurring substance abuse disorder. Submitted for publication, 2005.
77. Weiss RD, Greenfield SF, Najavits LM, et al. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry 1998;59:172-4.
78. Rychtarik RG, Connors GJ, Dermen KH, et al. Alcoholics Anonymous and the use of medications to prevent relapse: An anonymous survey of member attitudes. J Stud Alcohol 2000;61:134-8.
79. Farren CK, Hameedi FA, Rosen MA, et al. Significant interaction between clozapine and cocaine in cocaine addicts. Drug Alcohol Depend 2000;59:153-63.
80. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet. 1999;36:425-38.
81. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: A pharmacokinetic perspective. CNS Drugs 2001;15:469-94.
82. Bozikas VP, Papakosta M, Niopas I, et al. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. Eur Neuropsychopharmacol 2004;14:39-44.
83. McEvoy JP, Scheifler PL, Frances A. The expert consensus guideline series: Treatment of schizophrenia 1999. J Clin Psychiatry 1999;60(suppl 11):1-80.
84. Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series: Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64(suppl 12):1-100.
85. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65:500-8.
86. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, 2nd edition. Am J Psychiatry 2004;161(suppl 2):1-56.
87. Department of Veterans Affairs and Department of Defense. Management of Psychoses, MODULE J: Psychoses and Schizophrenia Treatment. Washington, DC: VA/DoD Evidence-Based Clinical Practice Guideline Working Group, Veterans Health Administration, Department of Veterans Affairs, and Health Affairs, Department of Defense, May 2004. Office of Quality and Performance publication 10Q-CPG/PSY-04 (Can be accessed at www.oqp.med.va.gov/cpg/PSY/psy_cpg/content/ ModJ/modA_fr.htm).
88. Albanese MJ, Khantzian EJ, Murphy SL, et al. Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry 1994;151:780-1.
89. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine. Am J Psychiatry 1995;152:959.
90. Buckley PF. Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia. J Subst Abuse Treat 1998;15:113-6.
91. Tsuang JW, Eckman TE, Shaner A, et al. Clozapine for substance-abusing schizophrenic patients. Am J Psychiatry 1999;156:1119-20.
92. Tsuang JW, Eckman T, Marder S, et al. Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J Clin Psychopharmacol 2002;22:629-30.
93. Buckley P, Thompson P, Way L, et al. Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine therapy. Am J Psychiatry 1994;151:385-9.
94. Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 1998;33:95-101.
95. Lee ML, Dickson RA, Campbell M, et al. Clozapine and substance abuse in patients with schizophrenia. Can J Psychiatry 1998;43:855-6.
96. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000;26:441-9.
97. Zimmet SV, Strous RD, Burgess ES, et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey. J Clin Psychopharmacol 2000;20:94-8.
98. Littrell KH, Petty RG, Hilligoss NM, et al. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat 2001;21:217-21.
99. Smelson DA, Losonczy MF, Davis CW, et al. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 2002;47:671-5.
100. Rosenheck R, Kosten TR. Risperdal for substance-dependent psychotic patients. Presented at the College on Problems of Drug Dependence Meeting, Bal Harbour, Florida, June 6, 2003.
101. Poling J, Kosten TR. Risperidone for substance dependent psychotic patients. Addictive Disorders & Their Treatment 2005;4:1-3.
102. Levin FR, Evans SM, Coomaraswammy S, et al. Flupenthixol treatment for cocaine abusers with schizophrenia: A pilot study. Am J Drug Alcohol Abuse 1998;24:343-60.
103. Rosenthal RN, Ozden A, Miner CR, et al. Effects of atypical neuroleptics in the dually diagnosed. Presented at Tenth Winter Workshop on Schizophrenia, Davos, Switzerland, February 5-11, 2000.
104. Green AI, Burgess ES, Dawson R, et al. Alcohol and cannabis use in schizophrenia: Effects of clozapine vs. risperidone. Schizophr Res 2003;60:81-5.
105. Smelson DA, Ziedonis DM, Losonczy MF, et al. A double-blind study comparing olanzapine to haloperidol for reducing cue-elicited craving in individuals with schizophrenia and cocaine dependence. Schizophr Res 2003;60:303.
106. Carol G, Smelson DA, Losonczy MF, et al. Alcohol and drug abuse: A preliminary investigation of cocaine craving among persons with and without schizophrenia. Psychiatr Serv 2001;52:1029-31.
107. Smelson DA, Losonczy MF, Kilker C, et al. An analysis of cue reactivity among persons with and without schizophrenia who are addicted to cocaine. Psychiatr Serv 2002;53:1612-6.
108. Brown ES, Nejtek VA, Perantie DC, et al. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord 2002;4:406-11.
109. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000;157:1835-42.
110. Batki SL, Dimmock J, Cornell M, et al. Directly observed naltrexone treatment of alcohol dependence in schizophrenia: Preliminary analysis. Alcohol Clin Exp Res 2002;26(suppl 5):470 (abstract).
111. Petrakis IL, O'Malley S, Rounsaville B, et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 2004;172:291-7.
112. Farren CK, O'Malley S. A pilot double blind placebo controlled trial of sertraline with naltrexone in the treatment of opiate dependence. Am J Addict 2002;11:228-34.
113. Zimmet SV, Strous RD, Burgess ES, et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey. J Clin Psychopharmacol. 2000;20:94-8.
114. Evins AE, Mays VK, Rigotti NA, et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001;3:397-403.
115. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002;52:53-61.
116. Weiner E, Ball MP, Summerfelt A, et al. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 2001;158:635-7.
117. Ziedonis DM, George TP. Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997;23:247-54.
118. Williams JM, Ziedonis DM. Addressing tobacco among individuals with a mental illness or an addiction. Addict Behav 2004;29:1067-83.
119. Williams JM, Ziedonis DM, Foulds J. A case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia. Psychiatr Serv 2004;55:1064-6.
120. DeQuardo JR, Carpenter CF, Tandon R. Patterns of substance abuse in schizophrenia: Nature and significance. Psychiatr Res 1994;28:267-75.
121. Negrete JC, Knapp WP, Douglas DE, et al. Cannabis affects the severity of schizophrenic symptoms: Results of a clinical survey. Psychol Med 1986;16:515-20.
122. Raphael B, Wooding S, Stevens G. Comorbidity: Cannabis and complexity. J Psychiatr Pract 2005;11:161-76.
123. National Association of State Mental Health Program Directors (NASMHPD) and National Association of State Alcohol and Drug Abuse Directors (NASADAD). Exemplary methods of financing integrated service programs for persons with co-occurring mental health and substance use disorders. Alexandria, VA and Washington, DC: NASMHPD-NASADAD Task Force on Co-Occurring Disorders; 2002.
124. National Association of State Mental Health Program Directors (NASMHPD) and National Association of State Alcohol and Drug Abuse Directors (NASADAD). Financing and marketing the new conceptual framework for co-occurring mental health and substance use disorders: A blueprint for systems change. Alexandria, VA and Washington, DC: Second National Dialogue of the Joint NASMHPD-NASADAD Task Force on Co-Occurring Disorders; 2002.
125. National Association of State Mental Health Program Directors (NASMHPD) and National Association of State Alcohol and Drug Abuse Directors (NASADAD) Joint Task Force on Co-Occurring Mental Health and Substance Use Disorders. The evolving conceptual framework for co-occurring mental health and substance use disorders: Developing strategies for systems change; Final Report, April, 2004 (Can be accessed at http://www.nasmhpd.org).
126. Ries RK. The dually diagnosed patient with psychotic symptoms. J Addict Dis 1993;12:103-22.